Use of hcg and lh in controlled ovarian hyperstimulation
AssigneeLaboratoires Seronosa
InventorYves Menezo
Life of this patent
Estimating the term…
Abstract
The invention provides a protocol leading to improved embryo implantation rates and/or decreased miscarriage rates in which hCG or LH, or a bio-analogue thereof, is administered during the follicular phase.
Claims32
A method for aiding implantation and/or decreasing miscarriage rates, comprising administering human chorionic gonadotropin (hCG), or an analogue thereof, in conjunction with controlled ovarian hyperstimulation (COH) in human patients using FSH, or an analogue thereof, starting before the 10th day after commencing FSH treatment.
A method for encouraging implantation and/or decreasing miscarriage rates of an embryo in a human patient, comprising administering human chorionic gonadotropin (hCG) or an analogue thereof, or human luteinising hormone (hLH), or an analogue thereof, before ovulation or ovulation triggering.
A pharmaceutical composition for use in conjunction with COH, for aiding implantation and/or decreasing miscarriage rates, comprising 25-1000 IU hCG, or an analogue thereof, or 125-7000 IU LH or an analogue thereof, per dosage.
A method for aiding implantation and/or decreasing miscarriage rates, comprising administering human luteinising hormone (hLH), or an analogue thereof, in conjunction with controlled ovarian hyperstimulation (COH) in human patients using FSH, or an analogue thereof, starting before the 10th day after commencing FSH treatment.
A kit for use in COH comprising 12 or more daily doses of FSH, or an analogue thereof, and 4 to 8 daily doses of hCG, or an analogue thereof.
A kit for aiding implantation of an embryo and/or decreasing miscarriage rates, comprising 4 to 8 daily doses of hCG, at about 25-1000 IU hCG/day, or an analogue thereof.
Dependencies are inferred from the claim text.